Drilldown: Medicines
Medicines > classes 
:
Empathogen or
Sedative-Hypnotic or
[[:Category:Hormone_replacement|Hormone replacement]]
:
Empathogen or
Sedative-Hypnotic or
[[:Category:Hormone_replacement|Hormone replacement]] Use the filters below to narrow your results.
generic:
brand:
None (25) ·
(none, never marketed) (1) ·
Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid (1) ·
Cytomel (oral), Triostat (IV) (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
Synthroid, Levoxyl, Tirosint, Unithroid, Euthyrox (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Melatonin receptor agonist (2) ·
Monoamine releasing agent (3) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) ·
'"`UNIQ--vote-00000032-QINU`"' Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic'"`UNIQ--ref-00000033-QINU`"'. (1)
uses:
None (45) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000033-QINU`"', '"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) ·
'"`UNIQ--vote-00000034-QINU`"', '"`UNIQ--vote-00000035-QINU`"' (1) ·
'"`UNIQ--vote-0000149A-QINU`"', '"`UNIQ--vote-0000149B-QINU`"', '"`UNIQ--vote-0000149C-QINU`"' (1)
starting dose:
None (45) ·
1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) ·
30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine (1) ·
Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
None (45) ·
15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg) (1) ·
25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) ·
5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat) (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1)
fda max:
routes:
onset:
duration:
halflife:
None (45) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
T4 ~7 days; T3 ~1 day'"`UNIQ--ref-00000036-QINU`"' (1) ·
~1 day (much shorter than T4's ~7 days)'"`UNIQ--ref-0000149D-QINU`"' (1) ·
~7 days (euthyroid); longer in hypothyroidism (~9-10 days), shorter in hyperthyroidism'"`UNIQ--ref-00000036-QINU`"' (1)
bioavailability:
None (45) ·
40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) ·
Not formally characterized in humans. (1) ·
Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' (1)
pregnancy:
None (45) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
First-line in pregnancy; dose typically increased 25-30% due to estrogen-driven rise in TBG and fetal demand. Lactation safe at physiologic doses.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 49 results in range #1 to #49.